How Much Does Tirzepatide Cost Without Insurance? (2026 Pricing)

Tirzepatide is the most effective weight-loss medication on the market today — and the most searched. The first question most people ask after side effects is the price. The honest answer depends on which version you take, whether you have insurance, and how you source it. Brand-name Zepbound® at pharmacy list price is over $1,000 a month. Compounded tirzepatide through telehealth can be a fraction of that. This guide walks through every realistic option and what you'd actually pay.

Quick price reference

Prices shift — Eli Lilly adjusts list pricing and self-pay programs frequently, and telehealth brands reprice often. These are representative as of mid-2026. Pallas pricing is cash-pay only; not billed to insurance.

Why there's such a huge gap

The gap between $1,300 brand-name Zepbound® and a few hundred dollars for compounded tirzepatide reflects very different products and regulatory pathways. Compounded medications are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Three structural factors drive most of the difference:

1. Patent and regulatory costs. Eli Lilly spent over a decade and billions of dollars developing, testing, and getting FDA approval for tirzepatide. Zepbound®'s price reflects the need to recoup those costs and fund future research. Compounded versions don't go through the same FDA approval process — they're prepared per-prescription by US-licensed compounding pharmacies under state pharmacy board oversight.

2. Manufacturing and supply. Brand-name Zepbound® ships as prefilled pens and single-dose vials manufactured in sterile facilities through a national distribution network. Compounded tirzepatide is prepared in smaller batches, typically shipped in vials with syringes. The overhead is dramatically lower.

3. Insurance infrastructure. Brand-name pricing assumes most patients are covered through insurance, where Lilly negotiates rebates with pharmacy benefit managers. The "list price" and the "net price insurance pays" are often very different — but if you're uninsured, you pay close to list. Compounded tirzepatide through telehealth skips the insurance middle entirely.

Brand-name pricing, unpacked

Zepbound® (tirzepatide, weight loss indication)

• List price: ~$1,300/month (as of 2026)
• With commercial insurance coverage: $0–$150/month depending on plan
• Self-pay single-dose vials via LillyDirect: ~$349 (2.5 mg) to ~$499 (5 mg) per month, lower doses only
• Without insurance (pen, higher doses): close to list price

Zepbound® is FDA-approved for chronic weight management. In the SURMOUNT-1 pivotal trial, participants on the 15 mg dose lost an average of ~20.9% of body weight at 72 weeks alongside lifestyle intervention. Coverage for weight loss is still inconsistent — most commercial plans exclude anti-obesity medications, and Medicare is legally prohibited from covering them. Lilly's self-pay vial program is the most meaningful recent change for cash patients, though it's limited to lower doses and a vial-and-syringe format.

Mounjaro® (tirzepatide, diabetes indication)

• List price: ~$1,100/month
• With Medicare Part D (if prescribed for diabetes): typically $35–$200/month
• With commercial insurance (for type 2 diabetes): often well-covered; coverage for off-label weight loss is inconsistent
• Without insurance: close to list price

Mounjaro® is FDA-approved for type 2 diabetes. Some patients have a provider prescribe it off-label for weight loss hoping for better coverage — but many plans now require a diabetes diagnosis code for Mounjaro® coverage.

Compounded tirzepatide pricing

Compounded versions are prepared by US-licensed compounding pharmacies on a per-patient basis when a licensed clinician documents a specific clinical need. Compounded tirzepatide is not a generic of Zepbound® or Mounjaro® and is not FDA-approved.

Typical compounded pricing through telehealth platforms:

Most platforms include the medication, provider visit, shipping, and ongoing messaging in the monthly fee. There is typically no separate pharmacy bill, no copay, no out-of-pocket surprise. Pallas pricing is cash-pay only; not billed to insurance.

What insurance actually covers in 2026

This is the most confusing part of GLP-1 pricing. Here's the practical breakdown:

Medicare (65+)

Medicare Part D is prohibited by federal law from covering medications prescribed solely for weight loss. Zepbound® is not covered for obesity. Mounjaro® can be covered for type 2 diabetes. As of 2024, Part D plans can cover certain GLP-1s for cardiovascular risk reduction in specific patients — but plans are not required to, and coverage is inconsistent.

Medicaid

Varies by state. Some Medicaid programs cover weight-loss GLP-1s; many do not. Call your state Medicaid office to confirm before starting.

Commercial insurance (employer plans, individual marketplace)

• About 25–30% of commercial plans cover weight-loss GLP-1s in 2026, though coverage is expanding
• Most plans require prior authorization — proof of BMI 30+ (or 27+ with a comorbidity), documented prior lifestyle intervention, and an in-network prescriber
• Step therapy is common — plans may require you to try older or cheaper options first
• Self-funded employer plans (most large employers) often specifically exclude weight-loss medications

What to actually do

1. Call the number on the back of your insurance card
2. Ask: "Do you cover Zepbound® for weight loss? What's my cost share, and what prior authorization is required?"
3. If covered: get the prior auth form, have your provider complete it, submit, expect a 1–2 week decision
4. If not covered: this is where self-pay vials or compounded telehealth become the practical alternatives

The real total cost of brand-name therapy

Even when Zepbound® is covered, patients often pay meaningful out-of-pocket costs. A realistic annual budget:

Year 1 with commercial insurance covering Zepbound®:

• Medication copay: $25–$150/month × 12 = $300–$1,800
• Provider visits: $0–$200 (varies by plan)
• Labs (baseline + annual): $100–$400
• Total: ~$400–$2,400

Year 1 without insurance (cash-pay brand-name pen):

• Medication: ~$1,300/month × 12 = $15,600
• Provider visits (cash PCP): $150–$400
• Total: ~$16,000+

Year 1 self-pay vials (LillyDirect, lower doses):

• Medication: ~$349–$499/month × 12 = $4,200–$6,000
• Note: limited to lower doses and the vial format; higher maintenance doses revert toward list price

Year 1 compounded telehealth (Pallas injection):

• $359/mo × 12 = about $4,300/year — all-inclusive

For most patients without coverage, self-pay vials or compounded telehealth are the only economically viable options for staying on therapy long term.

Hidden costs to watch for

• Dose escalation — tirzepatide titrates up over ~5 months. Some pharmacies charge more at higher doses; others don't. Ask. Lilly's self-pay vials are cheapest at the lowest doses.
• Refill lags — if a pharmacy is delayed, you may pay out of pocket for a partial emergency fill elsewhere
• Prior auth denials — a meaningful share of initial weight-loss prior auth requests are denied. You can appeal, but plan for it
• Medication breaks — if you stop, weight typically returns over the following year per the SURMOUNT-4 withdrawal data. Some patients end up paying for two rounds if they stop prematurely
• Lab work — some telehealth programs include baseline and follow-up labs; others don't. Cash lab work is $100–$300

Which option is right for your budget

Commercial insurance covers Zepbound®: Use it. Even with a copay, brand-name with full pharmacy support is generally the most reliable option.

No coverage, lower maintenance dose: Lilly's self-pay vials may be the cheapest brand-name path — but confirm your target dose is offered before you commit.

No coverage for any GLP-1: Compounded telehealth is a practical option. Compounded medications are not FDA-approved products and are not generic versions of brand-name drugs.

Medicare, no qualifying indication: Compounded telehealth or self-pay vials. Medicare Part D won't cover Zepbound® for weight loss.

Deciding between molecules? Read our semaglutide vs tirzepatide comparison and our Wegovy vs Zepbound comparison for the clinical and cost differences.

Frequently asked questions

Is compounded tirzepatide a generic version of Zepbound® or Mounjaro®? No. Compounded tirzepatide is not a generic of any FDA-approved product. There is no FDA-approved generic tirzepatide on the US market — tirzepatide is under patent. Compounded tirzepatide is prepared per-prescription by US-licensed compounding pharmacies and is legally and regulatorily distinct from FDA-approved generic drugs. Compounded products are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.

Can I use HSA or FSA funds for tirzepatide? Yes, typically. Tirzepatide prescribed by a licensed provider is an eligible medical expense for HSA and FSA accounts. Most telehealth platforms provide receipts suitable for reimbursement. Check with your plan administrator to confirm specific rules.

Why is Zepbound® cheaper through LillyDirect than at my pharmacy? Lilly's self-pay vial program is a direct-to-patient channel that bypasses pharmacy and pharmacy-benefit-manager markups. It's offered in a single-dose vial format at lower doses, which is why the price is lower than a retail pen prescription. Higher maintenance doses are not always available through the vial program.

Is compounded tirzepatide more expensive than compounded semaglutide? Usually slightly, yes. At Pallas, compounded tirzepatide injection is $359/mo versus $269/mo for compounded semaglutide injection — reflecting the more complex dual GIP / GLP-1 molecule. Microdose tiers are lower for both.

Does Pallas require insurance? No. Pallas plans are cash-pay only — not billed to insurance, no insurance processing. This is what lets us keep flat, transparent pricing. Patients can separately submit receipts to HSA/FSA accounts.

Bottom line: If insurance covers Zepbound®, use it. If not, Lilly's self-pay vials (for lower doses) and compounded telehealth are the practical alternatives at a fraction of cash-pay pen pricing — note that compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Pallas compounded tirzepatide injection is $359/mo all-inclusive, cash-pay only.